Trial
NCT02352753
Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Osteogenesis Imperfecta
Intervention
Denosumab
Why stopped
The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-28